Patent Grant
6946120
The present invention relates to a vehicle system for a pharmaceutical composition comprising a piperidinopyrimidine derivative. More particularly minoxidil and to a pharmaceutical composition incorporating the vehicle system. Minoxidil is a pharmaceutically active ingredient having several indications including use as a hair growth stimulant.
Minoxidil has poor solubility in water and ethanol and pharmaceutical preparations currently marketed only contain a small percentage of minoxidil. That is, below 5%.
Numerous formulations comprising minoxidil have been published in the prior art including U.S. Pat. Nos. 4,139,619, 4,820,512, 5,104,646, 5,225,189, 4,938,953, 4,596,812, 5,006,332, 5,156,836 and 5,643,942. Many of the formulations require (or would require where the amount of minoxidil is greater than 5%) a very high percentage (often in the range of 30 to 50%) of propylene glycol or a similar glycol product in order to improve the solubility of minoxidil. Due to the viscosity and tack of propylene glycol, large amounts of propylene glycol or similar agents in a composition are not pharmaceutically or cosmetically elegant and may be unacceptable to the consumer. In addition, high concentrations of propylene glycol may cause local irritation and hypersensitivity upon application to the scalp.
It would accordingly be a significant advance in the art if a composition could be provided which would permit the inclusion of an increased percentage of the active ingredient, but without the disadvantages associated with a high propylene glycol concentration.
Accordingly, it is an object of the present invention to overcome, or at least alleviate, one or more of the difficulties and deficiencies related to the prior art. These and other objects and features of the present invention will be clear from the following disclosure.
Accordingly, the present invention in a first aspect provides a pharmaceutical composition for topical administration, including, as the pharmaceutically active component,
at least 5% by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;
an acid in an amount to substantially completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;
a solvent composition including a solvent selected from water and/or a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight.
Applicants have surprisingly discovered that by adjusting the acid concentration of the composition the solubility of the piperidinopyrimidine derivatives may be significantly increased without the necessity of utilising large amounts of propylene glycol or optionally by excluding propylene glycol altogether. Accordingly the total amount of active in the composition may be significantly increased. In a preferred form, the pharmaceutically active component is present in amounts of approximately 5 to 25% by weight, preferably approximately 5 to 15% by weight, more preferably approximately 7.5 to 12% by weight.
Preferably the piperidinopyrimidine derivative is minoxidil. Preferably the minoxidil is present in the form of a salt. The salt may include acetate, citrate, succinate. benzoate, hydrochloride, sulphate, phosphate or lactate. Preferably an acetate or lactate salt of minoxidil is used. The acetate or lactate salts may exhibit enhanced solubility and improve the ability to incorporate increased amounts of the active component in the composition.
In a preferred form the acid is added in an amount sufficient to provide an apparent pH to the composition of approximately 7.0 or less. The apparent pH of the composition is preferably between approximately 5.0 to 7.0, more preferably between 6.0 to 6.5. Any suitable acid may be used to adjust the pH, including mineral acids, such as hydrochloric acid, sulphuric acid, nitric acid and phosphoric acid, or organic acids such as citric acid, acetic acid, succinic acid, or maleic acid, or mixtures thereof. Acetic acid or lactic acid is preferred.
In a preferred form the acid is present at a level that provides at least 0.01 Normal acid. Alternatively, the acid is present in an amount equal to, or greater than, the amount of the piperidinopyrimidine derivative in Normal amounts.
Preferably the lower alcohol is ethanol. The ratio of water to ethanol is preferably from approximately 9:1 to 1;9, more preferably approximately 1:1 to 1:3, by volume.
Preferably, the co-solvent includes benzyl alcohol. The benzyl alcohol may be present in amounts of approximately 2.5 to 95% by weight, preferably approximately 5 to 40% by weight, based on the total weight of the pharmaceutical composition.
Alternatively, or in addition the co-solvent may include a polyhydric alcohol, for example a polyol selected from the group consisting of 1,3-butylene glycol. propylene glycol, preferably glycol 200 (PEG 200), polyethylene glycol 400 (PEG 400), hexylene glycol and dipropylene glycol, or glycerol. When propylene glycol is present, it may be present in amounts of approximately 10% by weight or less, preferably approximately 5% by weight, or less.
In compositions comprising 5% of minoxidil or greater, it is preferred to include benzyl alcohol in the composition. The benzyl alcohol may be present in amounts of up to 85% by weight, based on the total weight of the pharmaceutical composition.
In a preferred form the co-solvent system includes water and benzyl alcohol wherein the benzyl alcohol is in an amount of approximately 40 to 100% by weight, based on the total weight of the co-solvent system
In a preferred form the water is present in an amount no greater than 60% by weight.
In a preferred aspect, the pharmaceutical composition includes
approximately 5 to 12% by weight, based on the total weight of the composition, of a minoxidil or a minoxidil acid salt;
approximately 88 to 95% by weight of a solvent composition including
and less than 10% by weight, propylene glycol.
The final presentation of the composition may be any suitable topical pharmaceutical preparation and may include solutions, lotions, ointments, mousses, foams, sprays, aerosols, shampoos and/or conditioners, gels, creams, pastes, and other preparations known in the art. The composition may also include other ingredients such as preservatives, buffers, stabilisers, propellants and the like.
Preferably the pharmaceutical composition is a mousse composition. The mousse composition may include a suitable propellant, for example hydrocarbons or chlorofluorocarbons. Alternatively the pharmaceutical composition may be a gel composition. The gel composition may include a suitable gelling agent, e.g. a cellulose derivative. A hydroxy propyl cellulose, for example that sold under the trade designation Klucel M, has been found to be suitable.
Where an aerosol formulation is used, the aerosol formulation may be a homogeneous, aqueous-alcoholic emulsion system. The aerosol formulation upon actuation produces a stabilized, homogeneous, expandable foam which breaks easily with shear. A composition of this type is sometimes referred to as a “mousse”.
In a further preferred aspect, the pharmaceutical composition according to the present invention may further include an effective amount of a skin penetrating agent.
Suitable skin penetrating agents include alcohols such as dodecanol and oleyl alcohol; amines. such as isopropyl amine, diisopropyl amine, triethyl amine, triethanol amine, diisopropanolamine and ethylene diamine; carboxylic acids, such as oleic acid, linoleic acid and linolenic acid; esters, such as dibutyl sebacate, dibutyl phthalate, butyl benzoate and ethyl caprate; and others, such as Azone, N methyl pyrollidone, bile salts and urea.
All of the compositions herein may be actuated using propellants known per se in the pharmaceutical or cosmetic fields. Such propellants include hydrocarbons such as propane, isobutane or dimethyl ether and chlorofluorocarbons such as P-12, P114, and a 40:60 mixture thereof.
In the pharmaceutical composition according to the present invention, in addition to the above essential components, general purpose components ordinarily used in hair treatment compositions can be formulated, within a range which does not impair the effect of the present invention, including vitamins such as vitamin B.sub.6, vitamin E and derivatives thereof, and biotin; hair generating agents or hair generating aids such as panthothenic acid and derivatives thereof, glycylrrhetic acid and derivatives thereof, nicotinic acid esters such as benzyl nicotinate, cyclosporins, carpronium chloride, cepharanthine, oxendolone, diazoxide, minoxidil, and ethynylesteradiol; antibacterial agents such as hinokitiol, hexachlorophen, phenol, benzalkonium chloride, cetylpyridinium chloride, undecylenic acid, trichlorocarbanilide, and bithionol; refrigerants such as menthol; drugs such as salicylic acid, zinc and derivatives, thereof, and lactic acid and alkyl esters thereof; amino acids such as arginine; oil components such as olive oil, squalane, fluid paraffin, isopropyl myristate, higher fatty acids, and higher alcohols; perfumes; antioxidants; UV-ray absorbers; dyes-; humectants; thickeners; perfumes; colour additives and the like.
In a still further aspect of the present invention, there is provided a method for the treatment of hair loss and related indications in humans, which method includes
providing
a pharmaceutical composition for topical administration, including, as the pharmaceutically active component.
an acid in an amount to substantially completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;
a solvent composition including a solvent selected from water and/or a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight; and
applying topically to the human scalp a therapeutically or prophylactically effective amount of the pharmaceutical composition.
The hair loss may be related to any of the forms of alopecia including male pattern alopecia. Related indications may include weakening of hair strength, loss of hair colour and the like.
Preferably the pharmaceutically active component includes a minoxidil or a minoxidil salt, more preferably a minoxidil acetate, succinate or citrate salt.
More preferably the pharmaceutical composition includes
approximately 5 to 12% by weight, based on the total weight of the composition, of a minoxidil or a minoxidil acid salt;
approximately 88 to 95% by weight of a solvent composition including
and less than 10% by weight, propylene glycol.
The present invention will now be more fully described with reference to the accompanying figures and examples. It should be understood, however, that the description following is illustrative only and should not be taken in any way as a restriction on the generality of the invention described above.
In each of the following examples it was necessary to add an appropriate amount of acid to ensure equivalent acid normality. The standard technique for such an adjustment is to measure the apparent pH of the solution.
In the examples, the apparent pH of each formulation was measured once prepared. The measured taken as the apparent pH due to the high proportion of organic modifiers in the formulations. Typically, 0.5% (w/w) glacial acetic acid (0.1M) would be used in the formulation, which would equate to a pH of 1.0 in an aqueous system when no other components are contributing to the pH of the solution.
The apparent pH of the final formulated solution was measured at 6.24.
The apparent pH of the final formulated solution was measured at 6.24.
The apparent pH of the final formulated solutions was measured at 6.0 and 6.5 for formulations 3a and 3b, respectively.
There appear to be no obvious gross stability issues associated with any of the formulations. The levels of minoxidil were assayed in formulations 1 and 3a after they had been stored for one and three months at 4° C. and 50° C. No measurable loss in potency was observed.
An aqueous gel was prepared by adding 0.75% (w/w) Klucel M (hydroxypropyl cellulose) to Example 4. The viscosity of the gel was measured at 2400 cPoise at 20° C.
Investigations were carried out to determine which of the components present in Example 7 (10% (w/w) minoxidil solution) were contributing to the solubilisation of minoxidil. The investigation was split into three sections:
The solubility determination involved preparation of saturated solutions of minoxidil in the media of interest. These solutions were then filtered (0.45 μm) and analysed against a standard curve by means of direct UV spectroscopy.
Aqueous Unbuffered Solubility of Minoxidil
The aqueous solubility of minoxidil was found to be 2.2 mg/mL.
Effect of Co-Solvent
The solubility of minoxidil was determined in each of the co-solvents, benzyl alcohol, glycerol, propylene glycol and ethanol. Additionally, the solubility of minoxidil was determined in 10% (w/w) solutions of each of the co-solvents, ethanol, propylene glycol and glycerol in water. A 4% (w/w) solution of benzyl alcohol was used since this was found to be the limit of the solubility of benzyl alcohol in water. The following table summarises the results of these studies.
Analysis indicated that of the systems studied only the use of pure benzyl alcohol would result in the desired 10% (w/w) minoxidil solution.
Effect of Apparent pH
Attempts were made to prepare saturated solutions of minoxidil in acetate buffers at apparent pH's 2.5, 3.5, 4.6, 5.0 and 6.0. Saturated solutions were achieved with those pHs above the pKa of minoxidil (4.61), the results of which are summarised in the following table.
It was not possible to determine the solubility limits of minoxidil at pH's below it's pKa, as minoxidil was found to be extremely soluble in acidic media and the buffer used had insufficient capacity to avoid the drift in pH observed with additions of minoxidil to the solution. The maximum minoxidil concentration studied was 22 mg/mL and was found to be completely soluble in pH 2.5 and 3.5 solutions at this concentration. The following table outlines the maximum solubility that would be expected in an acidic aqueous media knowing the solubility of the base form of minoxidil is 2.2 mg/mL and assuming infinite solubility of the acid form of minoxidil.
Effect of Salt
Minoxidil base was used for these studies with the appropriate salt (acetate or HCl) formed in situ. As discussed above the use of low pH acetate buffers significantly increased the solubility of minoxidil.
The major factors affecting the solubilisation of minoxidil in an aqueous environment were found to be:
The type and proportion of co-solvents present in the formulation
The pH of the final formulated solution
The amount of minoxidil used
The acid form of minoxidil has been shown to be much more soluble in an aqueous environment. The use of co-solvents has been shown to enhance the solubility of the minoxidil free base. The co-solvents may also enhance the solubility of the acid form. The use of an appropriate salt enhances the solubility of the acid form of minoxidil. Therefore, a combination of these three factors may be used to optimise the solubility of minoxidil in a topical solution based formulation.
All the above examples were stored at room temperature and no crystallisation or precipitation was observed for at least 10 days.
Please note all percentages are based upon the total weight of the composition unless otherwise specified.
It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual features mentioned or evident from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.
It will also be understood that the term “comprises” (or its grammatical variants) as used in this specification is equivalent to the term “includes” and should not be taken as excluding the presence of other elements or features.
| Number | Date | Country | Kind |
|---|---|---|---|
| PP 3107 | Apr 1998 | AU | national |
The present application is a continuation and claims the benefit of earlier filed U.S. application Ser. No. 09/673,872, filed on Dec. 4, 2000, which is a National Phase application filed under 35 U.S.C. § 371 of PCT Application No.: PCT/AU99/00294, which PCT application claims priority to PP 3107 filed in the Australian Patent Office on Apr. 22, 1998 which is incorporated by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4139619 | Chidsey, III | Feb 1979 | A |
| 4596812 | Chidsey, III et al. | Jun 1986 | A |
| 4820512 | Grollier | Apr 1989 | A |
| 4828837 | Quinn et al. | May 1989 | A |
| 4866067 | Di Schiena | Sep 1989 | A |
| 4882182 | Halls et al. | Nov 1989 | A |
| 4888354 | Chang et al. | Dec 1989 | A |
| 4915934 | Tomlinson | Apr 1990 | A |
| 4938953 | Pena et al. | Jul 1990 | A |
| 4981678 | Tomlinson | Jan 1991 | A |
| 5006332 | Grollier | Apr 1991 | A |
| 5030442 | Uster et al. | Jul 1991 | A |
| 5041439 | Kasting et al. | Aug 1991 | A |
| 5104646 | Bolich, Jr. et al. | Apr 1992 | A |
| 5156836 | Uchikawa et al. | Oct 1992 | A |
| 5183817 | Bazzano | Feb 1993 | A |
| 5225189 | Pena | Jul 1993 | A |
| 5516504 | Tomlinson | May 1996 | A |
| 5571841 | Yu et al. | Nov 1996 | A |
| 5578599 | Diani et al. | Nov 1996 | A |
| 5643942 | Hester, Jr. et al. | Jul 1997 | A |
| 5753216 | Leitch et al. | May 1998 | A |
| 5783202 | Tomlinson et al. | Jul 1998 | A |
| 5788155 | Martin et al. | Aug 1998 | A |
| 5834014 | Weiner et al. | Nov 1998 | A |
| 5935554 | Tomlinson | Aug 1999 | A |
| 6211250 | Tomlinson et al. | Apr 2001 | B1 |
| 6231875 | Sun et al. | May 2001 | B1 |
| 6255313 | Suzuki et al. | Jul 2001 | B1 |
| 6267949 | Halls | Jul 2001 | B1 |
| 6284234 | Niemiec et al. | Sep 2001 | B1 |
| 6383471 | Chen et al. | May 2002 | B1 |
| 6419913 | Niemiec et al. | Jul 2002 | B1 |
| 20030157046 | Imamura et al. | Aug 2003 | A1 |
| Number | Date | Country |
|---|---|---|
| 0 211 268 | Feb 1987 | EP |
| 211268 | Feb 1987 | EP |
| 0 273 202 | Jul 1988 | EP |
| 0 331489 | Sep 1989 | EP |
| 0 160051 | Jan 1992 | EP |
| 0 599 819 | Mar 1994 | EP |
| 0 770 399 | May 1997 | EP |
| 1 070752 | Jan 2001 | EP |
| 62-036367 | Feb 1987 | JP |
| 63-045212 | Feb 1988 | JP |
| 63-150211 | Jun 1988 | JP |
| 01-68309 | Mar 1989 | JP |
| 01-068308 | Mar 1989 | JP |
| 01-068310 | Mar 1989 | JP |
| 64-68308 | Mar 1989 | JP |
| 64-68309 | Mar 1989 | JP |
| 64-68310 | Mar 1989 | JP |
| 2-502822 | Jun 1990 | JP |
| 9-5045387 | May 1995 | JP |
| 09071513 | Mar 1997 | JP |
| 09-188620 | Jul 1997 | JP |
| 9-188620 | Jul 1997 | JP |
| 9-188629 | Jul 1997 | JP |
| 9-98447 | Oct 1998 | JP |
| 2810040 | Oct 1998 | JP |
| 2810041 | Oct 1998 | JP |
| 10-265343 | Oct 1998 | JP |
| 10-121876 | Nov 1999 | JP |
| 10-158782 | Dec 1999 | JP |
| 11-349451 | Dec 1999 | JP |
| 11349451 | Dec 1999 | JP |
| WO 8302558 | Aug 1983 | WO |
| WO 8501876 | Sep 1985 | WO |
| WO 8600196 | Jan 1986 | WO |
| WO 8801863 | Mar 1988 | WO |
| WO 8807362 | Mar 1988 | WO |
| WO 8807362 | Oct 1988 | WO |
| WO 8907436 | Aug 1989 | WO |
| WO 9204419 | Mar 1992 | WO |
| WO 9416732 | Aug 1994 | WO |
| WO 9525500 | Sep 1995 | WO |
| WO 9627376 | Sep 1996 | WO |
| WO 9703638 | Feb 1997 | WO |
| WO 9712602 | Apr 1997 | WO |
| WO 9800179 | Jan 1998 | WO |
| WO 9823291 | Jun 1998 | WO |
| WO 8804896 | Jul 1998 | WO |
| WO 9852525 | Nov 1998 | WO |
| WO 9920250 | Apr 1999 | WO |
| WO 9953923 | Oct 1999 | WO |
| WO 0015193 | Mar 2000 | WO |
| WO 0066172 | Nov 2000 | WO |
| WO 0176541 | Oct 2001 | WO |
| WO 0176605 | Oct 2001 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20020172649 A1 | Nov 2002 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 09673872 | Dec 2000 | US |
| Child | 10124197 | US |
